SEC Comment Letter 0000000000-24-002754 to Evogene Ltd. (EVGN)
Evogene Ltd.
Date: March 13, 2024 · CIK: 0001574565 · Accession: 0000000000-24-002754
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277565
Letter
United States securities and exchange commission logo March 13, 2024 Ofer Haviv Chief Executive Officer Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel Re:Evogene Ltd. Registration Statement on Form F-3 Filed March 1, 2024 File No. 333-277565 Dear Ofer Haviv: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Juan Grana at 202-551-6034 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Mike Rimon, Esq.
Show Raw Text
United States securities and exchange commission logo
March 13, 2024
Ofer Haviv
Chief Executive Officer
Evogene Ltd.
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
Re:Evogene Ltd.
Registration Statement on Form F-3
Filed March 1, 2024
File No. 333-277565
Dear Ofer Haviv:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Juan Grana at 202-551-6034 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Mike Rimon, Esq.